News

Reviews Pipeline Therapeutics for Intercellular Adhesion Molecule 1 by Companies and Universities/Research institutes with the help of latest report

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) – Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Immunology, Central Nervous System, Genito Urinary System And Sex Hormones and Ophthalmology which include indications Cholangitis, Crohn’s Disease (Regional Enteritis), Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Liver Fibrosis, Multiple Sclerosis, Pancreatic Islet Transplant Rejection, Pouchitis, Refractory Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis and Ulcerative Colitis.

Report Source: https://www.themarketreports.com/report/intercellular-adhesion-molecule-1-major-group-rhinovirus-receptor-or-cd54-or-icam1-pipeline-review-h1

Scope

  • The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
  • The report reviews Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics and enlists all their major and minor projects

Purchase this report at: https://www.themarketreports.com/report/buy-now/1466935

Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1466935